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The efficacy and safety of oral amrinone were examined
in 17 patients with moderately severe to severe heart
failure that was refractory to standard medical therapy
and vasodilators. The short-term and 28 week response
to open amrinone therapy was assessed first, folIowed
by a placebo-controlled, double-blind withdrawal study
of two 13 week stages in nine patients. Rest and exercise
ventricular function were determined before and after
32 hours of amrinone; aerobic capacity was serialIy as-
sessed. After 2 hours, 1.64 mg/kg amrinone produced a
40% (p < 0.001) increase in cardiac output and a 32%
(p < 0.02) decrease in pulmonary wedge pressure with-
out altering heart rate or blood pressure. The exercise
cardiac index-wedge pressure curve obtained 32 hours
The long-term management of patients with chronic cardiac
failure remains a difficult problem. In patients who remain
symptomatic despite administration of digitalis and diuretic
agents, salutary hemodynamic benefits have been obtained
with various pharmacotherapeutic agents having positive
inotropic (I) or vasodilator (2) properties, or both, These
benefits have not necessarily been accompanied by an im-
provement in exercise performance (3,4) or an enhancement
of the patient's quality of life. Therefore, the search con-
tinues for an orally active compound that provides a sus-
tained improvement in cardiac performance, as well as effort
tolerance.
Amrinone is a synthetic cardiotonic agent with positive
inotropic and vasodilator properties (5). Its mechanism of
action is not entirely known, although it has been suggested
that amrinone may have properties of phosphodiesterase
inhibition (6). Administered either intravenously (7,8) or
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after the first oral dose was significantly shifted (p <
0.05) above control values. A sustained improvement in
maximal oxygen uptake was noted during long-term open
amrinone therapy.
Subsequently, seven of the patients randomized to
placebo therapy had a significant deterioration of symp-
toms or exercise tolerance, or both. After 4 weeks of
readministration of amrinone, clinical stability was once
again established and exercise tolerance was improved
by Weeks 8 to 16. Adverse effects of thrombocytopenia
(one patient) and hepatic dysfunction (one patient) at-
tributable to amrinone were observed. It is concluded
that amrinone is effective in the long-term treatment of
chronic cardiac failure.
orally (9) to patients with chronic severe heart failure re-
fractory to standard therapy, amrinone has been shown to
acutely increase rest cardiac output and decrease rest left
ventricular filling pressure without significant changes in
systemic arterial pressure or heart rate. The hemodynamic
response to upright exercise performance, measured within
24 hours of the initiation of intravenous amrinone admin-
istration, was also improved (10,11). In a small number of
patients followed up for 4 weeks on oral amrinone therapy,
aerobic capacity was increased (II) while no demonstrable
tolerance to the drug has been observed (12).
Amrinone, therefore, appears to be a promising agent
for the treatment of chronic cardiac failure. To date, how-
ever, long-term controlled trials with amrinone have not
been reported. Accordingly, we examined the efficacy of
oral amrinone in the long-term treatment of heart failure,
as well as the invasive and noninvasive measurements of
exercise performance in a controlled, double-blind with-
drawal study.
Methods
Patients. The study group consisted of 17 patients (7
women and 10 men with a mean age of 56 years [range 45
to 67]) with stable, chronic, moderately severe to severe
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heart failure. Four had ischemic heart disease as judged by
a previously documented myocardial infarction or electro-
cardiographic or enzyme criteria, or both. Seven patients
had congestive cardiomyopathy of uncertain origin despite
cardiac catheterization or echocardiographic studies, or both.
Mitral or aortic valve incompetence, or both, with poor
ventricular function accounted for the heart failure in the
remaining six patients. Two of these six patientshad under-
gone mitral valve replacement, but had residual myocardial
dysfunction; the other four were judged to be poor surgical
risks for valve replacement. Six patients had chronic atrial
fibrillation; II had normal sinus rhythm.
As part of their baseline evaluation, all patients were
interviewed and underwent physical and chest X-ray ex-
amination, nuclear ejection fraction measurement by gated
blood pool imaging with technetium-99m, 24 hour ambu-
latory electrocardiographic Holter monitoring and a pul-
monary function test. Weekly diaries were kept to establish
a baseline subjective measurement of the patients' functional
capacity and to assess relative quality of life. Each patient
gave a history of exertional breathlessness or fatigue, or-
thopnea and paroxysmal nocturnal dyspnea. despite the long-
term administration of digitalis and one or more diuretic
agents and was, therefore, considered to be refractory to
standard medical therapy. No patient had significant ob-
structive airway or restrictive pulmonary disease. Fourteen
patients had also receiveda trial of one or more vasodilators
before entering the study. These included one patient who
had received an oral nitrate preparation alone and four pa-
tients who had received it in combination with another vas-
odilator. Ten had received hydralazine alone or in combi-
nation with another vasodilator, and six patients underwent
individual trials of prazosin, captopril or trimazosin. All
vasodilators were given in maximal doses tolerated by the
patient. Because of the persistent symptoms of failure and
no improvement in functional capacity, the response to vas-
odilators was considered inadequate in all. Vasodilator ther-
apy was discontinued a minimum of 2 weeks before entry
into the study. No patient had an exacerbation of cardiac
failure on withdrawal of vasodilator therapy.
As further requirements for entry into the study, the dos-
age of diuretic drugs and digitalis for each patient had to
be stable for at least 4 weeks, as did the degree of symp-
tomatic and clinical failure. Exercise tolerance had to be
reproducible (± 10%) on two occasions measured days to
weeks apart. Finally, all patients had to meet one or more
of the following criteria: a left ventricular filling or pul-
monary wedge pressure greater than 15 mm Hg, a cardiac
index less than 2.5 liters/min per rn", an ejection fraction
less than 30% and cardiomegaly on chest X-ray film esti-
mated by a cardiothoracic ratio greater than 50%.
The fun ctional capacity of each patient and the severity
of cardiac failure were objectively graded on the basis of
maximal oxygen uptake (V02 max) achieved during pro-
gressive upright treadmill exercise and the criteria previ-
ously reported from this laboratory (13). Six patients had
moderately severe failure (class C) achieving a V02 max
between 10 and 15 cc/min per kg, while II patients had
severe failure (class D) achieving a V02 max of less than
10 cc/min per kg. V02 max was defined as V02 being
unchanged « 1co/min per kg) despite an increase in tread-
mill work.
Hemodynamic monitoring and exercise testing. All
patients gave informed written consent; the investigational
protocol andconsent form wereapprovedby the institutional
reviewboardof thishospital. Afteradmittanceto our clinical
research center, a flotation catheter was inserted at the bed-
side through an antecubital vein to obtain baseline right
heart, pulmonary artery and pulmonary capillary wedge
pressures and cardiac output by thermodilution technique.
Patients were then taken by wheelchair to our exercise fa-
cility where they underwent upright, progressive treadmill
exercise to exhaustion to establish V02 max. The treadmill
program, consisting of 2 minute stages during which speed
or grade, or both, is varied, has been reported elsewhere
(14). Right atrial, pulmonary arteryand pulmonary capillary
wedge pressures were measured during each stage of ex-
ercise; mixed venous blood was obtained during the last 30
seconds of each stage and its oxygen content subsequently
determined.
Before and throughout exercise, respiratorygasexchange
was monitored as previously described (13) to determine
the response in oxygen uptake, carbon dioxide production
and minute ventilation. Cardiac output by Fick principle
was calculated for each exercise stage from V02 and the
arteriovenous oxygen difference. The response in exercise
performance, including hemodynamic measurements, was
determined in each patient before and after 32 hours of oral
amrinone therapy (discussed later).
Drug protocol: in-hospital phase. After 60 minutes or
more of recovery from exercise, patients were given oral
amrinone (Sterling-Winthrop) . Previous experience with in-
travenous amrinone in this laboratory (II ) has suggested
that a mean unit dose of 1.8 ± 0.1 mg/kg dry body weight
would produce a salutary hemodynamic effect, that is, an
increase in cardiac output greater than 30% and a decrease
in pulmonary wedge pressure greater than 30%. Bioavail-
ability data (15) suggest that intravenous and oral dosing
should be similar. Because oral amrinone during this study
was only available in 75 and 100 mg capsules, the unit oral
dose was slightly lower (1 .6 ± 0.1 mg/kg). Rest hemo-
dynamic variables and cardiac output were measured 30
minutes before and at 0.5 , I, 2, 3, 4 and 5 hours after
amrinone administration to establish the hemodynamic re-
sponsecurve. Plasmasamples wereobtained throughoutthe
dosing interval for determination of amrinone and its N-
acetyl metabolite plasma concentrations by high perform-
ance liquid chromatography (16).
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Figure 1. The acute hemodynamic responseof cardiac output and
pulmonary wedge pressure after a single oral dose of amrinone
(1.6 ± 0.1 mg/kg).
period or when the clinical condition of the patient had
deteriorated significantly to warrant breaking the blinded
code and determining whether placebo was being received.
Statistical analysis. Patients were grouped into either
functional class C or D according to their V02 max. The
averaged results for each group are presented as mean ±
standard error of the mean. Group comparisons were made
using the one-factor analysis of variance and the modified
t test (18). In addition, group comparisons were always
made with equal numbers of patients in each group. Thus,
whenever a patient died or withdrew from the study, the
baseline data in that case were not used in subsequent com-
parisons. In accordance with the Bonferroni method, a prob-
ability (p) value of less than 0.05/k was considered statis-
tically significant ("k" is the number of comparisons
performed for a given set of data) (18). For example, when
the acute response in cardiac output was being statistically
compared with baseline, a total of six comparisons were
performed. Accordingly. p would have to be less than 0.008
for the increases in cardiac output to be considered statis-
tically significant.
50
Results
Amrinone: in-hospital phase. Cardiac index and pul-
monary wedge pressure. With the patient in the supine po-
sition, the mean cardiac index was 1.9 ± 0.2 liters/min per
Oral amrinone administration was continued on an every
8 hour basis. One to 2 hours after the fourth (32nd hour)
dose of amrinone had been given, patients were returned to
the exercise laboratory with the right heart catheter in place
and a repeat exercise test was performed to V02 max. Respi-
ratory gas exchange, cardiac output and the hemodynamic
response to exercise were measured as before. These de-
terminations represented the exercise response to steady-
state levels of amrinone, because mean amrinone half-life
in these patients were 4.8 ± I. 0 hours (17).
Patients were discharged 24 hours later on a regimen of
oral amrinone, 1.6 ± 0.1 mg/kg every 8 hours, for long-
term treatment before the placebo-controlled withdrawal phase
of the study.
Drug protocol: outpatient phase. Patients were fol-
lowed up weekly for 4 weeks and then at biweekly intervals
for the remainder of the study. Office visits included a diary
review of symptoms and daily weight, a capsule count to
assess compliance, physical examination and blood and urine
determinations. Concomitant medications, such as digoxin
and diuretic drugs, were maintained at baseline dosage un-
less diuretic dosage could be reduced on the basis of symp-
tomatic improvement or the appearance of intravascular vol-
ume depletion. Exercise testing utilizing noninvasive
respiratory gas exchange and chest X-ray examination were
periodically performed. Open label amrinone therapy was
continued for an average of 25 weeks (range 18 to 30) before
the double-blind, placebo withdrawal phase.
Eight patients did not complete the open label portion
of the trial. These included: three class D patients (severe
failure) who died suddenly during Weeks 1, 4 and 12, re-
spectively; two class D patients who developed an inter-
current illness unrelated to their cardiac condition at Weeks
16 and 29, respectively; one class D patient who developed
an increased paravalvular leak around her mitral valve pros-
thesis 4 weeks into therapy and underwent successful cor-
rective surgery; one class C patient (moderately severe fail-
ure) who proved unreliable on follow-up visits after 14
weeks; and one class C patient who developed abnormal
liver function tests that resolved after amrinone withdrawal
and recurred on rechallenge with the drug 12 weeks later.
Randomization to the controlled withdrawal phase was,
therefore, carried out in nine patients (four class C, five
class D). Diuretic drug and digitalis dosages remained un-
changed for at least 6 weeks before the double-blind, pla-
cebo withdrawal phase.
These nine remaining patients underwent a two-phase
study (13 weeks per phase). The first phase was a double-
blind randomization with the patient assigned to amrinone
or placebo therapy. During the second phase, only those
patients receiving amrinone underwent a second
randomization.
All nine patients were subsequently placed on open am-
rinone therapy, either at the completion of the randomization
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m2 and the mean pulmonary wedge pressure was 22 ± 3
mm Hg. The mean cardiac output and pulmonary capillary
wedgepressureresponsesof the 17patientsgivenan average
unit dose of oral amrinone of 1,64 ± 0,05 mg/kg are il-
lustrated in Figure 1. Within 30 minutesafter oral amrinone
administration, the cardiac output had increased 26 ± 5%
(p < 0.001) with a concomitant decrease in pulmonary
wedge pressure of 8 ± 10%. A peak increase in cardiac
output of 40 ± 6% (p < 0.001) was observed 2 hours after
drug administration with a simultaneous peak decrease in
wedge pressure of 33 ± 12% (p < 0.02). The salutary
hemodynamic effects were sustained for 5 hours. Note-
worthy are two patients who had a marked (44 and 80%,
respectively)decrease in filling pressure to less than 14 mm
Hg, 2 hours after a single dose of oral amrinone. Despite
this large decrease in filling pressure, their cardiac output
was significantly increased(49 and 51%, respectively) over
control values.
The increase in cardiac output was temporally related to
the attainment of peak plasma amrinone concentrations. Peak
concentrations ranged from 0.5 to 4.2 JLg/ml and occurred
0,5 to 2 hours after drug administration.
BLood pressureandheartrate. The control meanarterial
pressure of the study group was 90 ± 2 mm Hg, with a
corresponding heart rate of 77 ± 2 beats/min. At the time
of the peak hemodynamic effect of amrinone, mean arterial
pressure (87 ± 3 mm Hg) and heart rate (80 ± 2 beats/min)
were unchanged. This was the case throughout the 5 hour
Figure 2. For each stage of exercise, cardiac index is shown as
a function of pulmonary wedge pressure before and 32hours after
amrinone treatment for patients with moderately severe (class C)
and severe (class D) heart failure. The additional number ofpoints
with amrinone reflects the ability of the patients to exercise to
higher levels of work.
monitoring period. Supraventricular or ventricular tachy-
cardia was not observed during the dosing interval.
Exercise hemodynamics. Before amrinone, cardiac in-
dex and wedge pressure increased with exercise in both
classes (Fig. 2). For the class C patients (moderately severe
failure), the mean peak exercise wedge pressure was 28 ±
6 mm Hg and the correspondingmaximal cardiac index was
4.1 ± 0.3 liters/minper rrr'. In contrast, the class D patients
(severe failure) reached a higher wedge pressure of 36 ±
7 mm Hg and a lower cardiac index of 3.0 ± 0.3 liters/min
per rrr' during exercise.
After four doses of amrinone, both class C and D patients
were able to walk additional stages on the treadmill. Fur-
thermore, the cardiac index-wedgepressure curves for both
classes were shifted to the left, indicating a significant (p
< 0.05) hemodynamic improvement (Fig. 2). After amri-
none, the maximal cardiac index for class C patients im-
proved to 5.3 ± 0.5 liters/min per m2 at a corresponding
wedge pressure of 27 ± 8 mm Hg. Thus, at similar filling
pressures as before amrinone, patients could generate a higher
cardiac output and sustain it for longer periods. Likewise,
the class D patients improved their maximal cardiac index
to 4.0 ± 0.4 liters/min per rrr', while lowering maximal
wedge pressure to 28 ± 5 mm Hg. The mean plasma con-
centration of amrinone at steady state was 0.87 ± 0.21
JLg/ml.
Amrinone: outpatient phase. Exercise performance.
(Fig. 3). At baseline, the mean maximal oxygen uptake
(\102 max) was 12.5 ± 0.7 cc/min per kg for class C
patients (moderately severe failure) and 8.7 ± 0.3 cc/min
per kg for class D patients (severe failure). After steady
state plasma levels of amrinone had been achieved, the
aerobic capacity of class C patients was improved 18% (p
< 0.05) to a \102 max of 14.8 ± 0.9 cc/min per kg.
Similarly, the class D patients improved their aerobic ca-
pacity 22% (p < 0.05) to 10.6 ± 0.6 cclmin per kg.
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This significant improvement in exercise performance as
compared with baseline was sustained throughout the 28
week period. For the three class C patients who undertook
an exercise test after 28 weeks of amrinone therapy, the
\102 max continued to be significantly (p < 0.05) improved
(14.9 ± 0.6 cc/min per kg) over the baseline value of 12.0
:t 1.0 cc/min per kg , as it did for the six class D patients
(l 0.5 ± 0.6 versus 9.0 :t 0.3 cc/min per kg; p < 0.05).
Functional capacity . In addition to the objective mea-
surement of aerobic capacity ; each patient was assessed
clinically and by their subjective functional capacity. Weekly
diaries were reviewed to determine any change in the pa-
tients' qual ity of life. Table I lists the results of this analysis
for II patients who were on continuous amrinone therapy
for more than 12 weeks . Importantly, six patients (55%)
had a reduction of their diuret ic requirements while in the
study , without subsequent weight gain. More than 90% of
the patient s reported their ability to walk a flight of stairs
without pause and a marked improvement in daily walking
capacity. Nine patients (82%) stated that with amrinone they
were able to complete all household chores with ease. Four
patients (36%) (two class C and two class D) were able to
perform more vigorous chores such as mowing the lawn or
washing the car. Three patients previously unemployed be-
cause of disabilit y return ed to work . The remaining seven
patients were able to participat e in volunteer o~ service
activities.
. Heart size. Four patients had a clear reduction in radio-
graphic heart size as measured by the cardiothoracic ratio .
The average decrease for this subset was 13% (range 7 to
19), the most striking example of which is illustrated in
Figure 4. The remaining patients had no significant change
in cardiothoracic ratio .
Randomization phase. Nine patients were random ized
to the double-blind, placebo phase of the study; four had
moderate (class C) and five severe (class D) heart failure.
Figure 5 depicts the response in maximal aerobic capacity
obtained dur ing exercise for all nine pat ients durin g base-
line , open label therapy , double-blind randomization and
subsequent rechallenge with amrinone .
Aerobic capacity. All of the nine patients who were ran-
domized demonstrated a sustained improvement in aerobic
capacity. At the time of the first 13 week random ization ,
four patients (three class C and one class D) were assigned
to placebo while the remaining one class C and four class
D patients received amrinone. During this period, one pa-
tient developed a seve re respiratory infection with subse-
quent clin ical deterioration and a possible drug interact ion
with erythromycin. Thi s necessitated breaking the code arid
discovering that she had been taking amrinone at the time
of her illness. She was subsequently placed on open therapy
CLASS 0
TIME DURING AMRINONE THERAPY
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Figure 4. Serial chest X-ray films of one
patient taken during the course of the amri-
none protocol: baseline, showingcardiomeg-
aly (upper left panel); after 14 weeks of
open label amrinone therapy, demonstrating
a markedreductionin heartsize (upper right
panel); after 14 weeks of placebo adminis-
tration with recurrence of moderate cardio-
megalyand bilateralpleuraleffusions(lower
left panel); and after 10 weeks of readmin-
istration of amrinone, againshowing a marked
reduction in heart size (lower right panel).
and has continued to do well for more than 52 weeks of
continuous therapy, sustaining a significant improvement in
exercise performance over baseline. The remaining eight
patients including the four patients receiving placebo, ex-
hibited no clinically apparent change in their failure or sig-
nificant alteration in exercise performance throughout the
first 13 weeks. Two of the four patients treated with placebo,
however (both class C), demonstrated a progressive dete-
rioration in aerobic capacity that became more pronounced
by Week 14. In one of these patients, bilateral pleural ef-
fusions and cardiomegaly became present (Fig. 4).
Placebo administration. At the point of second random-
ization, the four patients receiving amrinone were randomly
assigned to placebo while the other four continued to receive
placebo. It should be noted that the double-blind nature of
this two-phase period was still preserved. During this 13
week period, a variable decline occurred in the exercise
tolerance and symptomatic improvement that was achieved
during open therapy. Two patients in class C and three
patients in class D developed significant worsening of their
symptoms and had markedly reduced subjective and objec-
tive exercise tolerance. This marked deterioration occurred
in less than 2 weeks of placebo therapy for three of the
patients (one in class C and two in class D). The other two
patients (one in class C, one in class D) required a full 18
weeks of placebo therapy before clinical worsening occurred
to such a degree that the code was broken. The progression
of cardiac failure symptoms was so severe in three of these
patients that they required hospitalization.
Three patients, two in class C and one in class D failed
to show a significant deterioration in symptoms while re-
ceiving placebo. One class C patient demonstrated a sus-
tained improvement in exercise capacity over baseline, while
the remaining two patients returned to baseline aerobic ca-
pacity. Thus, seven of the eight patients who completed the
entire randomization period of 26 weeks had a serious de-
terioration of symptoms or exercise tolerance, or both, as
a result of receiving placebo.
Return to open therapy. By 4 weeks of the return to
open label amrinone therapy, the three class C and four
class D patients whose condition had deteriorated during
placebo administration were once again clinically stable.
The concomitant medical regimen of all seven patients was
identical to that used during the first open label phase after
initial restabilization. No increase in maintenance diuretic
dosage was required to improve their clinical symptoms or
aerobic capacity after amrinone was reinstituted.
Of the three class C patients who demonstrated a decrease
in their \102 max during placebo administration, two re-
turned to their previously augmented aerobic capacity at-
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Discussion
Heart disease is the leading health problem in the United
States. In 1965, it was estimated that 3 of every 1,000
persons in the United States with heart disease had cardiac
failure that limited their lifestyle and shortened their survival
(19). In 1980, the incidence of heart failure had increased
dramatically; in fact, 400,000 hospitalized persons were
discharged with this diagnosis (National Center for Health
Statistics, unpublished data). Heart failure is the most com-
mon mortal disorder in hospitalized patients with heart dis-
ease (20). With current medical therapy including vasodi-
lators, the 2 year survival rate of patients with severe heart
failure is 30% or less (21). In light of the clear need for
more effective therapy for both the short- and long-term
management of patients with cardiac failure, an increasing
number of pharmacologic approaches have emerged for the
management of these patients (2,22,23).
Limitations of study. Before reviewing our experience,
a number of shortcomings inherent to this study should be
discussed. First, this study, although controlled and cov-
ering a period of 12 months or longer, involves only a small
number of patients. Our ability to evaluate patients with
advanced heart failure, whose prognosis is poor, over a long
period of time is difficult. Cause and effect relations of side
effects are obscured by the multiple medications that these
patients receive, often including one or more diuretic drugs,
digitalis, potassium chloride and antiarrhythmic or antico-
agulant agents, or both. In addition, these patients often
have other acute and chronic illnesses that occasionally in-
terrupt their stability and require additional therapeutic in-
tervention. The incidence of dropouts from this study as a
result of these problems is similar to our previous experi-
ences (14,24).
Another potential shortcoming of this study relates to its
design and the use of drug withdrawal to assess drug effi-
cacy. Although recommended as a useful approach (25),
the withdrawal design has several limitations. These include
bocytopenia without overt bleeding occurred in one patient
(97,000 mrrr') on 1.8 mg/kg of amrinone, and was corrected
with a reduction in dose to 1.3 mg/kg. One patient developed
elevation of hepatic transaminases to 20 times control within
2 months of amrinone administration, compatible with hep-
atitis. Amrinone was discontinued and liver function tests
returned to baseline within 2 weeks. Amrinone was rein-
stituted only to have the elevation of transaminases recur
within several days. Amrinone was not continued. This
patient died 2 weeks later in heart failure. Two patients
developed a persistent asymptomatic yellowish discolora-
tion of the fingernails and toenails. Holter electrocardio-
graphic monitoring after 12 weeks of amrinone therapy did
not reveal an alteration in the baseline frequency of cardiac
arrhythmia.
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tained before randomization by 8 weeks of open label am-
rinone therapy. The condition of the third patient was also
improved, although his exercise performance had only re-
turned to control level at the time of reevaluation. All four
class D patients returned to an improved exercise capacity
compared with baseline after reinstitution of amrinone.
Side effects. Six of the 17 patients had adverse effects
during the trial. One patient developed renal insufficiency
and profound fatigue after the concomitant administration
of erythromycin (prescribed for an upper respiratory infec-
tion) and amrinone. The antibiotic was discontinued and
she subsequently experienced no adverse effects during 52
weeks of amrinone therapy. Another patient had a localized
erythematous, maculopapular rash that resolved with a re-
duction in amrinone dosage. A moderate level of throm-
Figure 5. The response in maximal aerobic capacity for nine
patients, four with moderately severe (class C) and five with severe
(class D) heart failure during baseline, open label therapy, double-
blind randomization and rechallenge with amrinone.
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"carryover" effects, whereby a favorable response induced
by the drug may be sustained during the withdrawal phase,
and complicate the evaluation. For example, a marked re-
duction in heart size would be partially sustained during
randomization despite the administration of placebo. As a
result, a longer withdrawal period may be necessary to ne-
gate this persistent beneficial effect. Furthermore, there is
the dilemma of determining when the heart failure state will
reestablish itself and to what degree. There is no reason to
expect that the new equilibrium state and its attendant neu-
rohumoral characteristics achieved during withdrawal will
necessarily resemble the steady state of failure present dur-
ing the baseline stabilization period. This would certainly
be the case if diuretic drugs were reduced during open label
therapy and the patient was randomized to treatment with
less saluretic agents.
Finally, any study conducted to assess the efficacy of
therapy requires that an objective sensitive measure of the
severity of failure be available and monitored serially. For
this purpose we have chosen maximal oxygen uptake, which
has been shown to predict cardiac reserve and functional
capacity (13). However, it does not necessarily characterize
exercise performance or symptoms at submaximal levels of
work. Moreover, it is not known whether measured aerobic
capacity can be used to detect subtle changes in cardiovas-
cular function that may occur during drug withdrawal. De-
spite these shortcomings, this trial suggests that amrinone
was effective in the treatment of chronic cardiac failure.
Effects of amrinone. In this study, amrinone was given
to 17 patients with moderately severe to severe heart failure
refractory to standard medical therapy and vasodilators. When
measurements were made acutely, 1.6 mg/kg of oral am-
rinone exerted its salutary hemodynamic effects by increas-
ing cardiac output at rest by 40% while simultaneously
decreasing left ventricular filling pressure to a similar extent
without changing heart rate or mean arterial pressure. The
ability of this compound to improve ventricular function
during exercise was also demonstrated. The increment in
myocardial contractile state with an agent having positive
inotropic properties permits greater muscle fiber shortening
without the same dependence on fiber length (26). Hence,
a reduction in filling pressure and volume greater than that
obtained with pure vasodilatoragents may be possible (27,28).
A reduction in filling pressure may help to attenuate the
exertional dyspnea these patients typically experience during
exercise.
Comparisons with other drugs. Ideally, pharmacol-
ogic interventions designed for the long-term treatment of
heart failure should improve not only myocardial perform-
ance but also blood flow to each end organ according to its
metabolic requirements, An obvious increase in aerobic ca-
pacity of working muscle was apparent after amrinone
administration and was accompanied by an improved V02
max. Such responses have not been observed during short-
term vasodilator therapy, where exercise cardiac output in-
creases, but arteriovenous oxygen difference narrows and,
therefore, oxygen consumption is not enhanced (3,29,30).
Recent studies from this laboratory (31) indicate that even
though leg blood flow was increased after hydralazine
administration, the aerobic capacity of the working leg mus-
cles was not enhanced, suggesting that a shunting of blood
flow to less metabolically active tissues had been produced
by this nonspecific vasodilator. Moreover, we were not able
to demonstrate an improvement in aerobic capacity with
long-term hydralazine therapy (32), or in a controlled study
of a beta-adrenergic agonist in similar patients (24). In con-
trast, the present experience demonstrated after 32 hours of
oral amrinone therapy a significant improvement in aerobic
capacity that was sustained for 28 weeks. Subjectively, our
patients experienced less dyspnea and enjoyed a greater
freedom of activity. Fairly vigorous activities became pos-
sible on a routine basis for some patients with severe heart
failure. Objectively, in 55% of the patients improvement
was great enough to permit a decrease in diuretic dosage
without subsequent weight gain.
Amrinone withdrawal and readminstration. The ne-
cessity of performing placebo-controlled trials as part of any
investigational drug evaluation is obvious. Nine patients
entered the double-blind amrinone withdrawal phase of our
study. Of the eight patients who completed the 26 weeks
of randomization, seven had a serious deterioration of symp-
toms or exercise tolerance, or both, after receiving placebo.
The temporal relation between placebo administration and
the exacerbation of the heart failure state, however, was
widely disparate. Deterioration occurred within 2 weeks for
three patients, all of whom were in remarkably stable con-
dition for more than 20 weeks of open label amrinone ther-
apy. Two other patients exhibited a slower progression of
disability with placebo that may represent a "carry over"
effect. All patients again had an improvement in aerobic
capacity after readministration of amrinone.
Side effects. The side effect profile of amrinone requires
comment. Adverse effects such as fever, thrombocytopenia
and gastrointestinal disturbance have all been reported after
amrinone therapy (8-11,33). In our study, amrinone had to
be discontinued in one patient because of hepatic dysfunc-
tion clearly attributable to the drug. Regrettably, the patient
died shortly thereafter of heart failure.Mild thrombocyto-
penia (100,000 to 150,000 mrrr') occurred in most patients;
moderate thrombocytopenia (50,000 to 100,000 mrrr') ap-
peared to be dose-related in one patient and was not asso-
ciated with overt bleeding. Further studies are required to
elucidate alterations in amrinone clearance and drug inter-
action and to establish its therapeutic to toxic ratio. In this
respect, a more rapid assay of amrinone plasma levels may
facilitate the correlation of side effects and amrinone con-
centration, allowing more intelligent utilization of the drug.
Although not observed in this study, gastrointestinal upset
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with epigastric cramping occurred in three patients in a
previously reported experience (II). The broader distribu-
tion of concomitant medications throughout the day and
administration of amrinone with meals was often helpful in
alleviating these symptoms.
Effecton morbidity andmortality. Final consideration
must be given to the influence of any new therapy on mor-
bidity and mortality. To assess these end points, larger trials
of much longer duration are needed. Nine patients com-
pleted the 54 week study. Three patients died within the
first 12 weeks of the study; two others developed intercurrent
illnesses. The morbidity and mortality of heart failure are
extremely high (21,34), and our group of patients proved
no exception. We are extremely encouraged, however, that
9 of the 17 study patients remain well at the time of this
report. All have been receiving amrinone for more than 12
months of continuous therapy.
We sincerely appreciate the technical expertise and dedication of Tom
Nusbickel and David Ward and the secretarial assistance of leannette Forte.
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